After all the commotion on Friday, AMRN was -5% today.
Although peak-sales estimates for Vascepa are all over the map and the drug’s patent is in litigation, one thing is clear: the fully-diluted enterprise value is about $8.8B.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”